About: Potential of plants to produce recombinant protein products

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Potential of plants to produce recombinant protein products Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Potential of plants to produce recombinant protein products
Creator	Park, Ky Wi, Soo
Source	PMC
abstract	Plants have great potential as photosynthetic factories to produce pharmaceutically important and commercially valuable biomedicines and industrial proteins at low cost. The U.S. Food and Drug Administration (U.S. FDA) has approved the drug Elelyso (taliglucerase alfa) produced by carrot cells for treatment of type 1 Gaucher’s disease in 2012. The commercial potential of biomedicines produced by molecular farming has dramatically improved due to the success of an experimental drug called ZMapp, which has immunological activity in Ebola patients. A cocktail of three monoclonal antibodies was produced in tobacco (Nicotiana benthamiana) plants (Chen and Davis 2016). At present, very few drugs made by this technology have been approved by worldwide authorities such as the U.S. FDA. However, plants have been proposed as a novel paradigm for commercial production of proteins over the next decade. In recent years, leading researchers on molecular farming have given more priority to the area of animal-free therapeutic proteins such as parenteral and oral vaccines. Although plant-based platforms have considerable advantages over traditional systems such as bacterial and animal systems, there are several obstacles to commercial-scale production, especially with regards to improving the quality and quantity of plant-produced biologics and industrial materials. One of the biggest barriers to commercialization of this technology is the intense scrutiny of these new plant varieties by regulatory agencies and the public as well as the high costs associated with their regulatory approval.
has issue date	2016-12-08(xsd:dateTime)
bibo:doi	10.1007/s12374-016-0482-9
bibo:pmid	32288513
has license	no-cc
sha1sum (hex)	c19210b74bda75c3930bf91d2bc4d0896dbc3dee
schema:url	https://doi.org/10.1007/s12374-016-0482-9
resource representing a document's title	Potential of plants to produce recombinant protein products
has PubMed Central identifier	PMC7101786
has PubMed identifier	32288513
schema:publication	J Plant Biol
resource representing a document's body	covid:c19210b74bda75c3930bf91d2bc4d0896dbc3dee#body_text
is schema:about of	named entity 'Recombinant' named entity 'Plants' named entity 'carrot' named entity 'Inducible expression' named entity 'molecular farming' named entity 'immunogenic' named entity 'Samsun' named entity 'biotechnology' named entity 'pharming' named entity 'Gaucher's disease' named entity 'biomass' named entity 'therapeutic proteins' named entity 'molecular farming' named entity 'CFIA' named entity 'genetically modified organisms' named entity 'Korea' named entity 'protein' named entity 'tobacco' named entity 'pharmaceutical companies' named entity 'biologics' named entity 'bioreactors' named entity 'biological containment' named entity 'protein' named entity 'parthenocarpy' named entity 'FAS' named entity 'transgenic' named entity 'carrot' named entity 'monoclonal antibodies' named entity 'protein' named entity 'therapeutic proteins' named entity 'monoclonal antibodies' named entity 'biotechnology' named entity 'recombinant proteins' named entity 'RNA' named entity 'biomedicines' named entity 'U.S. FDA' named entity 'genetically modified' named entity 'INPACT' named entity 'ethanol' named entity 'viruses' named entity 'soybean' named entity 'pathogens' named entity 'gene expression' named entity 'replicon' named entity 'vaccines' named entity 'T-DNA' named entity 'biologics' named entity 'INPACT' named entity 'sunchon' named entity 'U.S. FDA' named entity 'chloroplasts' named entity 'protein expression' named entity 'transgenic' named entity 'E-mail' named entity 'proline hydroxylation' named entity 'recombinant protein' named entity 'transgene' named entity 'N. benthamiana' named entity 'recombinant proteins' named entity 'recombinant protein' named entity 'viral vectors' named entity 'soil microorganisms' named entity 'N. tabacum' named entity 'self-pollinating' named entity 'Mapp Biopharmaceutical' named entity 'recombinant proteins' named entity 'inherent safety' named entity 'Korea' named entity 'yellow dwarf' named entity 'protein' named entity 'nuclear genome' named entity 'soybean' named entity 'U.S. FDA' named entity 'ZMapp' named entity 'proline hydroxylation' named entity 'N. benthamiana' named entity 'human health' named entity 'biologics' named entity 'protein' named entity 'feed crops'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software